Skip to Content
Merck
CN
  • Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.

Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.

Protein and peptide letters (2009-06-13)
Caroline Brunetto de Farias, Laura Stertz, Rodrigo Cruz Lima, Flávio Kapczinski, Gilberto Schwartsmann, Rafael Roesler
ABSTRACT

The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
RC-3095, ≥95% (HPLC), lyophilized powder